Co-Creation Model: Tell us about your main strategic partners and how the partnership truly create value. For each Partner please include its type (business/social/public), its name, a short description, its key motivation to participate in the co-creation project, and the key contributions it is making in the co-creation project. Please follow the format displayed below:
Type of partner 1 [business]: pharmaceutical company
-An international mid-size pharmaceutical and life science company, that develops and commercials treatments for neurological and oncological diseases.
- Merck Serono is partnering with EspeRare to enable and accelerate the development of one of its dormant drug (Rimeporide), with the prospect of addressing Duchenne, a paediatric rare incurable disease.
-Merck Serono has granted EspeRare the rights to develop Rimeporide that has previously been developed for heart failure in Duchenne and provide an endowment to the foundation to develop the opportunity.
-Type of partner [social]: non-profit drug development engine
-A non-profit organisation established in Switzerland in 2013,that is recognised to be operating in the public's interest. Its mission is to drive and accelerated de development of treatment for rare diseases.
-In-line with its philanthropic Product Development Partnership model, through this collaboration EspeRare is enabling the development of unexplored assets for an incurable rare diseases.
-EspeRare is contributing its drug development know-how as well as its patient and expert network. It is driving animal studies, and is developing protocols for clinical trials. It has also raised public and philanthropic funds to co-finance the program activities.